Moreover, as new data increasingly become available regarding the predictive/prognostic interactions of various mutations in AML and how such combinations may define the choice of conventional versus new (targeted and non-targeted) therapies, the FLT3-ITD allelic burden will likely continue to have a role in AML prognostication [22,28,29,30,31,32,33,34], in addition to a role in treatment decision-making. This evidence concerns the gene FLT3 and acute myeloid leukemia.